Reported Saturday, Genentech's Phase III STARGLO Study Shows Columvi Increases Survival For Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma
Reported Saturday, Genentech's Phase III STARGLO Study Shows Columvi Increases Survival For Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma
据周六报道，Roche旗下的吉利德（Genentech）公司的第3期STARGLO研究表明Columvi可提高复发或难治性弥漫性大B细胞淋巴瘤患者的生存率。
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy –
使用Columvi联合化疗治疗复发性或难治性弥漫性B细胞淋巴瘤的患者，可以将死亡风险降低41%，达到主要研究终点。
– This Columvi combination could provide a much-needed off-the-shelf treatment option for people with transplant-ineligible R/R DLBCL –
这种Columvi联合方案可以为不能接受移植的复发性或难治性弥漫性B细胞淋巴瘤患者提供所需的现成治疗选择。
– Data were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at EHA 2024 as a late-breaking oral presentation –
数据被选为大会新闻发布会的特色板块，并以迟到的口头发言方式在EHA 2024的全会摘要会议上展示。